Nevertheless, new BCL2 targeted therapies for SCLC are still being investigated, and a recent phase I trial of a dual BCL2/BCL-xL inhibitor in combination with paclitaxel in 28 relapsed/refractory SCLC patients had an ORR of 25%, indicating that this therapy shows some promise, especially with patient selection (Table 1) [98]. The gene discussed is BCL2L1; the disease is small cell lung carcinoma.